Citeline

Our March edition of Citeline’s Patient Recruitment Pulse is now live! Finding patients for rare disease clinical trials can be an uphill battle. Fortunately, there are ways sponsors can ease the process. In this month’s Pulse, we explore key findings from our latest white paper, highlighting the challenges and best practices for recruiting patients in rare disease clinical trials. Explore the insights: vist.ly/4vha4 What have your rare disease patient recruitment experiences been like? Let us know in the comments.

🔬 We may be on the brink of one of pharma’s biggest breakthroughs — are we finally learning how to cross the blood–brain barrier? 👉 vist.ly/4vgc6 An article in @PharmaVoice referenced the finding from Citeline’s 2025 Annual Clinical Trials Roundup that the central nervous system therapeutic area saw trials increase 15% in 2024. 🌐 We’re watching a pivotal moment unfold. 💬 What do YOU think will be the biggest hurdle — or opportunity — as BBB‑crossing therapies move closer to mainstream development? Let us know in the comments!

AI is unlocking new possibilities in clinical trial planning: vist.ly/4vd7r One biotech team used predictive modeling and SmartDesign tools to shape protocol and site strategy, improving recruitment forecasts and feasibility outcomes.

Precision matters when patients are hard to find. Citeline PatientMatch uses AI + real‑world data to spot protocol‑matched patients earlier and speed enrollment. 🔗 vist.ly/4vc42 Follow @Citeline.

From seed to scale, the Pharma R&D Annual Review 2026 is almost ready to harvest. In our upcoming release, we unearth the forces shaping the global pipeline, highlighting where innovation is flourishing, which therapeutic areas are blossoming, and the approvals that could yield the biggest impact in 2026. Keep an eye out — we’ll be sharing a first look in this years infographic, to be released very soon.

Traditional approaches aren’t quite cutting it in today’s complex patient recruitment landscape. What to do instead? In @WorldPharmaToday, @MattHolms, Citeline’s Vice President, Commercial Patient Engagement & Recruitment, breaks down the need for a third generation of patient recruitment that incorporates data-linked patient identification at population scale: vist.ly/4v35a We’d love to hear your thoughts on third-generation patient recruitment in the comments.

Planning a Phase III trial in a new therapeutic area without prior experience is tough: vist.ly/4uwz5 One sponsor used RWD and AI to assess feasibility, validate CRO strategy, and select the right sites; resulting in a confident plan delivered in just three weeks.

Behind the scenes on Pharma R&D… We’ve been on location filming with Ian Lloyd as he does what he does best: digging deep into the drug development landscape to uncover what’s taking root, what’s gaining ground, and what’s set to bloom in 2026. Can you guess where we are? ✨Bonus points: what do you think this year’s theme is? Drop your guesses in the comments!

Our February Patient Recruitment Pulse is now available! vist.ly/4uth6 In addition to the ever-present buzz about AI, patient engagement and recruitment was a hot topic at SCOPE Summit 2026. The recruitment-focused program had two tracks, one on enrollment planning and patient recruitment, the other on diversity and retention, including the patient experience. Here are a few key takeaways, including excerpts from our own presentations on AI, the feasibility-informed protocol, and a case study on real-world enrollment. ———— Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets. #SCOPEsummit #ClinicalTrials #ProtocolDesign

As we look back on Rare Disease Day, we recognize the 300 million people worldwide living with a rare condition and the everyday realities they face. In rare disease research, awareness and engagement remain critical. They’re the drivers that help shorten diagnostic delays, strengthen trial visibility, and open the door to better patient experiences. Our latest white paper explores what it will take to advance rare disease recruitment with more patient-centered, data-driven strategies — on Rare Disease Day and throughout the year. Download it here: vist.ly/4unza #PatientRecruitment #ClinicalTrials #ShowYourStripes

It’s never been more important to incorporate diversity and representation in your clinical trials. Discover how we can broaden your patient recruitment reach: vist.ly/4ujk6

The market for KRAS-targeting oncology drugs could be poised to boom in the next few years. | vist.ly/4uid6 In a @PharmaVoice article on the KRAS space, Citeline analyst Neha Anand weighed in on the market performance of KRAS drugs like Amgen’s Lumakras and outlined how the next wave of KRAS therapies in the pipeline is taking shape. What do you think will be the biggest opportunity in this emerging market?

Lean biotech teams need smart, scalable support: vist.ly/4uftv Instead of training on complex tools, one sponsor relied on expert-led AI and real-world data solutions to guide protocol development and CRO selection–resulting in fewer delays & strategy built for growth.

🔍 What does real sustainability look like for OTC brands in 2026? It’s more complex (and more business‑critical) than most people think. In the latest Over the Counter episode, HBW Insight's David Ridley sits down with sustainability expert Steve Ramus to unpack the hard realities shaping ESG, eco‑pricing, and the future of pharmaceutical packaging. This is Part 2 of their deep‑dive conversation, and it delivers sharp, practical insights. 🎙️ Listen to the full episode: vist.ly/4ues4 🤔 What’s the single biggest barrier you see to accelerating sustainability in consumer health — cost, packaging innovation, regulation, or something else? Share in the comments below! #OverTheCounter2026

Our datasets pulse with the purpose of educating, engaging, and enrolling the precise patients you need for your clinical trials. Discover the new era of patient recruitment: vist.ly/4ub86

Curious about the risks and rewards of AI in pharma? vist.ly/4u78y Our latest webinar covers practical limitations, data protection concerns, and what’s next for the industry. ✔️US FDA’s AI Initiatives ✔️UK MHRA’s In Silico Trials ✔️Pharmacovigilance Innovation

How is AI shaping the future of medtech? vist.ly/4u5ba 
Check out our new infographic for headline stats, expert insights, and a global perspective on regulations and challenges.
Get a first look at the trends driving smarter, more personalized healthcare!

Our integrated solutions, powered by real-world data, help you reach potential clinical trial patients earlier and faster. Learn how we can accelerate your patient connections: vist.ly/4t2i5

Reaching patients with ultra-rare conditions requires a different kind of strategy. @SolGel partnered with Citeline to launch a 60-day, seven-country HCP awareness campaign around Gorlin syndrome — an extremely rare condition affecting one in 31,000 people. The campaign delivered exceptional engagement and multiple qualified referrals. Check out the case study: vist.ly/4tqi5 #PrecisionRecruitment #ClinicalTrials

Discover how CROs are staying on budget and ahead of schedule: vist.ly/4tm3z CROs are using feasibility modelling and AI-driven forecasting to avoid delays and control costs. With RWD guiding site selection and planning, teams can stay on track and protect margins.